Becton Dickinson — Aug 6, 2026 release

Page 14 BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION FROM NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES TO FREE CASH FLOW Nine Months Ended June 30, (Unaudited) A B C=A-B D=C/B 2026 2025 Change % Change Net Cash Provided by Continuing Operating Activities $ 2,104  $ 1,578  $ 526  33.3  % Capital Expenditures (376) (383) 7  (1.7) % Free Cash Flow $ 1,728  $ 1,195  $ 532  44.6  % Page 15 BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2026 GUIDANCE RECONCILIATION Full Year FY2025 Full Year FY2026 Guidance ($ in millions) % Change BDX Reported Revenues from Continuing Operations $ 18,544  FY2026 Reported Revenue Growth Low single-digit plus Illustrative Foreign Currency (FX) Impact ~+100 basis points FY2026 Revenue Growth (FXN) Low single-digit Page 16 BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2026 GUIDANCE RECONCILIATION CONTINUED Full Year FY 2026 Guidance Full Year FY2025 Total Company Reported Diluted Earnings per Share from Continuing Operations $ 3.81  Purchase accounting adjustments ($1.865 billion pre-tax) (1) 6.46 Integration costs ($127 million pre-tax) (2) 0.44 Restructuring costs ($270 million pre-tax) (2) 0.93 Transaction costs ($6 million pre-tax) (3) 0.02 Separation-related items ($3 million pre-tax) (4) 0.01 Product, litigation, and other items ($506 million pre-tax) (5) 1.75 Tax impact of specified items and other tax related (($443) million) (1.54) Adjusted Diluted Earnings per Share from Continuing Operations $ 11.90  $12.62 to $12.72 Reported % Change +6.1% to +6.9% (1) Includes amortization and other adjustments related to the purchase accounting for acquisitions. (2) Represents costs associated with integration and restructuring activities. (3) Represents transaction costs incurred in connection with the Advanced Patient Monitoring acquisition. (4) Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters. (5) Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2025 reflects charges of $98 million to Cost of products sold to adjust the estimate of certain future product remediation costs, charges of $297 million to Other operating expense, net , related to product liability and certain other legal matters, and charges of $38 million to Other expense, net , related to pension settlement costs. Page 17